Psoriasis
Program may help identify, manage cardiovascular risk in patients with psoriasis
Researchers have developed and piloted a centralized care coordination program to prevent cardiovascular events in patients with psoriatic disease, according to a study.
Getting Under the Skin With GPP: Understanding and Treating a Life-Threatening Dermatologic Disorder
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Phototherapy treatment for psoriasis, eczema not linked to increased skin cancer risk
Patients treated with phototherapy without psoralens do not experience higher incidence rates of skin cancer compared with the general population, according to a study.
Vtama cream combined with injectable biologics may improve psoriasis outcomes
Vtama cream 1% may be used in combination with an injectable biologic for the treatment of plaque psoriasis, according to a Schweiger Dermatology Group press release.
FDA approvals comprise majority of 2023 psoriasis news
The FDA’s approvals of various therapeutics comprised the majority of Healio Dermatology’s most read psoriasis articles this year.
Interleukin-23 inhibitors exhibit lowest paradoxical eczema risk in psoriasis treatment
While certain demographic factors were associated with a higher risk for paradoxical eczema among patients with psoriasis, treatment with certain biologic classes was not, according to a study.
Immunosuppressed patients may accrue skin cancer at higher rates than healthy patients
Patients with certain autoimmune and inflammatory conditions may develop cutaneous squamous cell carcinoma at higher rates than immunocompetent patients, according to a study.
Dermatology Clinical Case Challenge: Can You Diagnose This Patient?
Supported by an independent medical educational grant from Sanofi and Regeneron Pharmaceuticals.
Orismilast shows early efficacy in plaque psoriasis
The efficacy of orismilast is greater than placebo in patients with moderate to severe psoriasis, according to phase 2b trial results.
Bimzelx commercially available for plaque psoriasis
Bimzelx, which was approved by the FDA in October, is now commercially available for patients with moderate to severe plaque psoriasis, UCB announced in a press release.